---
title: Detect early Parkinsons via oculography
nct_id: NCT04731246
phase: NA
status: RECRUITING
sponsor: Association de Recherche Bibliographique pour les Neurosciences
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT04731246"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04731246"
last_fetched: "2026-05-10T14:02:19.016Z"
source: "Parkinson's Pathways (curated)"
---
# Detect early Parkinsons via oculography

**Goal (in five words):** Detect early Parkinsons via oculography

**Official Title:** Video-oculography and Parkinson's Disease: A Prospective Study

**Trial ID:** [NCT04731246](https://clinicaltrials.gov/study/NCT04731246)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Association de Recherche Bibliographique pour les Neurosciences
- **Target Enrollment:** 30 participants
- **Start Date:** 2021-07-07
- **Completion Date:** 2032-01
- **Conditions:** Parkinson Disease, Idiopathic
- **Interventions:** Video-oculography / Neuropsychological evaluations
- **Intervention Types:** OTHER

## Summary For Families

They want to detect subtle eye movement and thinking changes that could help confirm and track idiopathic Parkinson's disease in early to mid stages. The approach uses video-oculography to precisely record saccades, smooth pursuit, and fixation, paired with neuropsychological tests to link eye movement patterns with cognitive signs, and it is observational so it does not change or interact with levodopa or other Parkinson medications. Adults with clinically defined idiopathic Parkinson's, Hoehn and Yahr stage 1 to 3, a recent brain MRI and a DaTSCAN or F‑DOPA showing presynaptic dopaminergic loss, no major cognitive or other significant neurological or psychiatric disorders, French language ability, and a caregiver are eligible. Enrollment is small and focused, about 30 participants, so it is aimed at refining diagnostic markers rather than testing a treatment.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
\*Inclusion Criteria:

1. Male or Female;
2. Clinically defined idiopathic Parkinson's Disease (PD);
3. Brain MRI performed in routine care in the 12 months preceding inclusion;
4. Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation;
5. Hoehn \& Yahr score: 1 to 3;
6. Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted);
7. Neuro-cognitive disorders: absent or minor (according to DSM5);
8. Sufficient written and oral expression in French;
9. Covered by a health insurance system;
10. Written informed consent signed by the patient;
11. Presence of a caregiver.

    \* Exclusion Criteria:
12. Psychiatric comorbidity (except anxiety or mild to moderate depression);
13. Neurological comorbidity, if significant;
14. Brain MRI showing:

    1. significant cerebrovascular pathology (Fazekas I admitted),
    2. another brain disease, including stroke.
15. Major cognitive impairment;
16. Absolute exclusion criteria and "Red flags" of the 2015 criteria orienting towards another degenerative pathology of the extrapyramidal system:

    * Cerebellar syndrome
    * Vertical oculomotricity disorders on clinical examination
    * Motor symptoms restricted to the lower limbs
    * Bilateral and perfectly symmetrical parkinsonism
    * Early dystonia
    * Clinical profile suggestive of behavioral variant frontotemporal dementia (bvFTD)
    * Progressive aphasia or apraxia
    * Moderate or severe postural instability and / or early falls
    * Early bulbar dysfunction (dysarthria, swallowing disorders)
    * Ventilatory dysfunction (inspiration)
    * Severe dysautonomia
    * DOPA-resistance
    * Neuroleptic treatment or related
17. Normal MIBG myocardial scintigraphy (if performed).
```

## Locations (1)

- Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital, Monaco, Monaco _(43.7372, 7.4215)_
  - Solange HESSE — (CONTACT) — +377 99995599 — solange.hesse@chpg.mc
  - Kevin POLET — (CONTACT) — kevin.polet@chpg.mc
  - Sandrine LOUCHART DE LA CHAPELLE, MD-PHD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Solange HESSE — (CONTACT) — +377 99995599 — solange.hesse@chpg.mc
- Kévin POLET — (CONTACT) — kevin.polet@chpg.mc

---

*Canonical: https://parkinsonspathways.com/trial/NCT04731246*  
*HTML version: https://parkinsonspathways.com/trial/NCT04731246*  
*Source data: https://clinicaltrials.gov/study/NCT04731246*